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Background:  Most alcoholics experience periods of voluntary alcohol abstinence or 
imposed alcohol deprivation followed by a return to alcohol drinking.  The current study 
examined whether varenicline (VAR) reduces alcohol intake during a return to drinking after 
periods of alcohol deprivation in rats selectively bred for high alcohol drinking (the alcohol 
preferring or “P” rats).  
Methods:  Alcohol-experienced P rats were given 24-hour access to food and water and 
scheduled access to alcohol (15% and 30% v/v) for 2 h/d. After 4 weeks, rats were deprived 
of alcohol for 2 weeks, followed by reaccess to alcohol for 2 weeks, and this pattern was 
repeated for a total of 3 cycles. Rats were fed either vehicle (VEH) or VAR, in doses of 0.5, 
1.0 or 2.0 mg/kg BW, at 1 hour prior to onset of the daily alcohol reaccess period for the first 
5 days of each of the 3 alcohol reaccess cycles.  
Results:  Low dose VAR (0.5 mg/kg BW) reduced alcohol intake during the 5 days of drug 
treatment in alcohol reaccess cycles 1 and 2. Higher doses of VAR (1.0 mg/kg BW and 2.0 
mg/kg BW) reduced alcohol intake during the 5 days of treatment in all 3 alcohol reaccess 
cycles. The decrease in alcohol intake disappeared with termination of VAR treatment in all 
alcohol reaccess cycles.  
Conclusions:  The results demonstrate that VAR decreases alcohol intake during multiple 
cycles of  alcohol reaccess following alcohol deprivation in rats and suggests that it may  
prevent a return to heavy alcohol drinking during a lapse from alcohol abstinence in humans 
with AUD.    
 
Keywords: Varenicline, Alcohol, Alcohol-Preferring (P) Rats, Alcohol Deprivation, Alcoholism 
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Addiction to alcohol is one of the most prevalent addictions in the world and prevention and 
treatment are of paramount importance.  Alcohol use disorder (AUD), which encompasses 
the prior distinct disorders of alcohol abuse and alcohol dependence, is defined as a 
problematic pattern of alcohol use leading to clinically significant impairment or distress with 
at least 2 of 11 symptoms manifested within the past 12 months (American Psychiatric 
Association, 2013). Several characteristics are associated with AUD such as intake of 
alcohol that is greater, or over a longer period of time, than is intended, persistent desire to 
cut down alcohol use, disruption of other life obligations in order to access alcohol, craving of 
alcohol, and alcohol use that results in poor performance in other facets of life.   
Almost all alcoholics go through periods without drinking which are either voluntary or 
involuntary and the vast majority of alcoholics return to alcohol drinking (Anton et al., 2006; 
Dawson et al., 2007; Litten et al., 2013; Schuckit et al., 1997).  This pattern is colloquially 
called “falling off the wagon” or clinically called “relapse”. In fact, one of the strongest 
defining characteristics of alcoholism is alcohol relapse (Dawson et al., 2007).  Relapse is 
motivated by a desire to reduce alcohol withdrawal signs and symptoms which can last 
anywhere from hours to months but are usually greatest within the first three months 
following discontinuation of alcohol drinking (American Addiction Centers, 2016). Although 
relapse is a characteristic feature of alcoholism, definitions of relapse are remarkably varied.  
A recent review of the literature on AUD relapse concluded that there are at least 25 different 
definitions of alcohol relapse (Maisto et al., 2016)   Relapse ranges from being loosely 
defined as a return to drinking after alcohol abstinence (voluntary) or deprivation (imposed 
as in legal constraints) to being very strictly defined as consumption of a given amount of 
alcohol during a defined period of time.  Although the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-5) refrains from defining alcohol relapse, it is widely accepted that 
one of the most common characteristics of AUD is a return to drinking after periods of 
abstinence/deprivation. Relapse rates can vary from 90%, if relapse refers to ingestion of 
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one or more drinks (Edwards and Orford, 1977), to around 50%, if relapse refers to the 
return to pretreatment drinking levels (Paredes et al., 2008).  
 
Currently only three drugs are FDA approved to treat AUD: disulfiram, acamprosate, and 
naltrexone. Of these, naltrexone and acamprosate are the most widely used (O’Malley and 
Froehlich, 2003). Several reviews and meta-analyses have reported that these drugs are 
only moderately effective for treating alcohol relapse since relapse rates of 83% -86% are 
reported in individuals treated with acamprosate (Donoghue et al., 2015; Pilling et al., 2011; 
Rösner et al., 2010; Sinclair et al., 2016) and relapse rates of 83% -92%  are reported in 
individuals treated with naltrexone (Donoghue et al., 2015; Pilling et al., 2011; Sinclair et al., 
2016).  Identifying new medications for the treatment of AUD is of prime importance.     
 
Varenicline (VAR) is an α4β2 nicotinic acetylcholinergic receptor partial agonist that is 
marketed as CHANTIX® in the United States and as CHAMPIX® in Europe and elsewhere.  
VAR was FDA approved for smoking cessation in 2006.  Since then, evidence has 
accumulated that VAR also reduces alcohol intake in both rodents and humans.  In rodents, 
VAR reduces alcohol drinking (Chatterjee et al., 2011; Froehlich et al., 2016, 2017; Lacroix 
et al., 2017), operant self-administration of alcohol (Wouda et al., 2011), reinstatement of 
extinguished alcohol seeking (Funk et al., 2016) and flavor-induced alcohol drinking 
(Steensland et al., 2007). In humans, VAR reduces alcohol consumption (for review see 
Erwin and Slaton, 2014), in both alcohol dependent (Litten et al., 2013) and alcohol non-
dependent individuals (Mitchell et al., 2012) and in both smokers and non-smokers (Litten et 
al., 2013), although a reduction in consumption is not always seen (Schacht et al., 2014).  
VAR also reduces alcohol craving (Fucito et al., 2011) and the subjective reinforcing effects 
of alcohol (“high” or “intoxication”), and increases the likelihood of abstaining from drinking 
(McKee et al., 2009). VAR is a potentially attractive medication for alcohol relapse because it 
is effective when administered in clinically relevant doses (Faessel et al., 2006) and it lacks 
serious side effects in most patients (McKee et al., 2009; Stapleton et al., 2008). 
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Rodents that are selectively bred for high voluntary alcohol drinking, such as the alcohol-
preferring (P) rat line (Froehlich and Li, 1991; Li et al., 1979), are well suited for testing the 
efficacy of medications with the potential to reduce alcohol intake. We have previously 
reported that VAR blocks the expression of a genetic predisposition toward high alcohol 
drinking in alcohol-naïve P rats (Froehlich et al., 2017) and reduces alcohol intake 
throughout prolonged periods of treatment (Froehlich et al., 2016). The current study 
examined whether VAR can also decrease alcohol intake in rats during alcohol reaccess 
following repeated cycles of alcohol deprivation, a condition commonly experienced by 
individuals with AUD.   
 
MATERIALS AND METHODS 
Subjects 
Forty six adult male rats from the 78th generation of selective breeding for alcohol preference 
(P line) were purchased from the Indiana University Alcohol Research Resource Center. At 
the onset of the study, all rats were between 239-251 days of age. Rats were housed 
individually in stainless steel hanging cages that were located in an isolated vivarium with 
temperature controlled at 21±1oC, and with a 12 hour light/dark cycle with dark onset at 1000 
hours. Standard rodent chow (Laboratory Rodent Diet #7001, Harlan Teklad, Madison, WI) 
and water were available ad libitum.  All experimental procedures were in compliance with 
the NIH Guide for the Care and Use of Laboratory Animals in addition to being approved by 
the Indiana University Institutional Animal Care and Use Committee.  
 
Alcohol Solutions 
The 15% (v/v) and 30% (v/v) alcohol solutions were prepared by diluting 95% alcohol 
(ethanol) with distilled and deionized water.  Two different alcohol solutions were used 
because studies have shown that providing P rats with multiple concentrations of alcohol 
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increases alcohol intake (Bell et al., 2003). The two alcohol solutions were presented 
concurrently in separate calibrated glass drinking tubes, along with water, and daily fluid 
intakes were recorded to the nearest milliliter. To prevent the development of a side 
preference, the positions of the three drinking tubes were rotated daily.  Alcohol intake in 
milliliters was converted from ml alcohol/kg BW to g alcohol/kg BW prior to data analysis. 
 
Alcohol Drinking Induction 
All rats were provided with access to food, water, a 15% (v/v) alcohol solution and a 30 % 
(v/v) alcohol solution. Alcohol access was introduced using a “step-down” procedure as 
previously described (Froehlich et al., 2013a, b, 2016), and illustrated in Figure 1, to 
maximize alcohol intake during a daily 2-hour alcohol access period. After alcohol intake 
stabilized during the daily 2 hour alcohol access period, all rats were given imposed alcohol 
deprivation for 2 weeks followed by 2 weeks of reaccess to alcohol for 2 hours a day and this 
cycle of alcohol access followed by alcohol deprivation was repeated for a total of 3 cycles. 
During alcohol access, rats were given a daily 2-hour concurrent free-choice between 2 
concentrations of alcohol (15% and 30% v/v) from 1000 hours (onset of dark) to 1200 hours, 
7 days a week.  The following indices were recorded: daily alcohol intake (g/kg BW/2 hour) 
and water intake (ml/kg BW/day), and semiweekly body weight (g) for the duration of the 
study. 
 
Choice of drug dose 
VAR was used in doses of 0.5, 1.0 and 2.0 mg/kg BW.  Low doses of VAR are preferable to 
high doses because low doses are receptor specific and do not alter food consumption in 
rats.  VAR, like many other ligands, interacts with different receptor classes as a depending 
on the dose administered. The higher the dose, the less selective VAR becomes.  In doses 
above 3.0 mg/kg, VAR may lose  specificity for the α4β2 and/or the α7 nicotine acetylcholine 
receptors (Rollema et al., 2007) and a dose of 3.0 mg/kg VAR has been reported to 
decrease food intake in rats (O’Conner et al., 2010).  
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Drug Preparation and Oral Delivery 
Varenicline tartrate (VAR) (Pfizer Int., Groton, CT), in doses of 0.5, 1.0, and 2.0 mg/kg BW, 
was incorporated into flavored, star-shaped pieces of gelatin that were voluntarily consumed 
by the rats, as previously described (Froehlich et al., 2013a, b, 2016, 2017). The volume of 
each gelatin star (approximately 1.8 g) was determined by the body weight of each rat on a 
daily basis. The gelatin star was inserted through a hole in the front of the cage. All of the 
rats consumed the gelatin star within 1 minute.  Cages were checked to confirm that no 
small pieces of gelatin were dropped.  If pieces were dropped, which was rare, they were 
refed to the rat. Gelatin stars were fed once each day at 1 hour prior to onset of the daily 2-
hour alcohol access period because the half-life of VAR in the rat is short (4.0 ± 0.9 hours) 
(Obach et al., 2006). This oral drug delivery approach can be used for any water soluble 
drug that is orally active. It is well suited for chronic drug delivery because it eliminates 
stress and conditioned aversion to handling and eliminates the potential for harming the 
animal. 
Assigning Rats to Treatment Groups 
During the week prior to onset of the first alcohol deprivation, baseline alcohol and water 
intake were calculated for each rat over 5 consecutive days and the rats were ranked in 
descending order in terms of average daily alcohol consumption.  Rats were assigned to 
drug dose groups (0.0, 0.5, 1.0, or 2.0 mg/kg BW) in a manner that ensured that the groups 
did not differ in baseline alcohol intake prior to VAR administration as previously described 
(Froehlich et al., 2013a, b, 2016, 2017).   
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Experimental Design 
After completion of the alcohol step-down procedure and 4 weeks of access to alcohol for 2 
hours a day, all rats were given 3 cycles of alcohol drinking and imposed alcohol deprivation 
and were treated with either VAR or VEH during the first 5 consecutive days of reaccess to 
alcohol in each of the 3 cycles.  Each cycle involved alcohol deprivation for 2 weeks followed 
by 2 weeks of alcohol reaccess.  
 
The effects of VAR on alcohol drinking were assessed during reaccess to alcohol following 
each of the 3 alcohol deprivation periods. Rats were treated with VAR or VEH for the first 5 
consecutive days of each of the three reaccess cycles. The remaining days of each alcohol 
reaccess cycle were not accompanied by drug treatment, but alcohol access was maintained 
at 2 hours a day.  
 
Data Analysis 
Alcohol and water intake during the 2-hr daily alcohol reaccess periods were analyzed using 
2-way repeated measures (RM) analyses of variance (ANOVAs) (treatment x day, RM on 
day). When sphericity could not be assumed, as indicated by a significant Mauchly’s test 
(p<0.05), Greenhouse-Geisser was used to correct the degrees of freedom. Significant main 
effects and interactions were further analyzed using Dunnett’s pairwise multiple comparisons 
against a single mean (VEH). To assess the stability of alcohol intake prior to and following 
deprivation, alcohol intake during the last 5 days prior to onset of alcohol deprivation was 
compared with alcohol intake on day 1 of alcohol reaccess in the VEH group using a paired 
student’s t-test. 
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To determine whether the effect of VAR persisted following termination of treatment in each 
of the 3 alcohol reaccess cycles, mean alcohol intake prior to alcohol deprivation was 
compared to mean alcohol intake on the day following termination of VAR treatment using a 
1-way ANOVA.  
Significance was accepted at p<0.05 (unless otherwise stated) and data are presented as 
mean ± SEM. Data were analyzed for extreme scores using the Dixon extreme score test 
with a conservative cutoff of p<0.01. No values were found to be significant outliers. 
RESULTS 
Alcohol Intake during Alcohol Drinking Induction  
When given an 8-hour free-choice between two alcohol solutions (15% v/v and 30% v/v) and 
water for 17 days, rats of the P line attained an average daily alcohol intake of 4.2 g 
alcohol/kg BW (Fig. 1). When access to alcohol was reduced to 4 hours a day for 11 days, P 
rats consumed approximately 3.0 g alcohol/kg BW daily and when access to alcohol was 
further reduced to 2 hours a day for 27 days prior to initiation of alcohol deprivation, P rats 
consumed an average of 2.0 g alcohol/kg BW per day. These levels of alcohol consumption 
agree well with our prior findings in P rats under similar scheduled alcohol access conditions 
(Froehlich et al., 2013a, b, 2015, 2016). 
Effect of VAR on Alcohol and Water Intake Following the First Alcohol Deprivation Cycle 
With regard to alcohol intake during the first 5 days of alcohol reaccess, there was a 
significant effect of treatment F (3, 42) = 9.8, p<0.001, day F (4, 168) = 3.3, p<0.05, and a 
treatment X day interaction F (12, 168) = 1.8, p<0.05 (Fig. 2). Dunnett’s multiple 
comparisons against a single mean (VEH) revealed that VAR, in doses of 1.0, and 2.0 mg/kg 
BW, each reduced alcohol intake (p<0.01, and p<0.001, respectively), and that the lowest 
dose of VAR (0.5 mg/kg BW) showed a strong trend toward a reduction in alcohol intake 
(p=0.054) (Fig. 2). Dunnett’s multiple comparisons for each dose against a single mean 
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(VEH) within day, revealed that the lowest dose of VAR (0.5 mg/kg BW), reduced alcohol 
intake only on day 2 of treatment (p<0.05).  A higher dose of VAR, 1.0 mg/kg BW, reduced 
alcohol intake on days 2-5 of treatment (days 2 and 4; p<0.001; days 3 and 5, p<0.01), and 
the highest dose of VAR (2.0 mg/kg BW), reduced alcohol intake on days 2-5 of treatment 
(day 2, p<0.001; days 3, 4, and 5, p<0.01).  
With regard to alcohol intake after termination of drug treatment, there was no effect of prior 
drug treatment indicating that the effect of VAR disappeared following termination of 
treatment. 
With regard to the stability of alcohol intake prior to and following deprivation, when alcohol 
intake prior to alcohol deprivation (mean of 5 days) was compared to alcohol intake during 
reaccess to alcohol on day 1, there was no effect of treatment, a significant effect of day, F 
(1, 42) = 7.4, p<0.01, and no treatment X day interaction (Fig. 2). 
With regard to water intake during the first 5 days of the alcohol reaccess period 
(Greenhouse-Geisser correction, ε=0.83), there was no effect of treatment, a significant 
effect of day F (3.3, 139.8) = 8.8, p<0.001, and no treatment X day interaction (Table 1).  
Effect of VAR on Alcohol and Water Intake Following the Second Alcohol Deprivation Cycle 
With regard to alcohol intake during the first 5 days of the alcohol reaccess period, there was 
a significant effect of treatment F (3, 42) = 6.4, p<0.01, no effect of day, and no treatment X 
day interaction (Fig. 3). Dunnett’s multiple comparisons against a single mean (VEH) 
revealed that VAR, in doses of 0.5, 1.0, and 2.0 mg/kg BW, each reduced alcohol intake 
(p<0.05, p<0.001, and p<0.01, respectively) (Fig. 3).   
With regard to alcohol intake after termination of drug treatment, there was no significant 
effect of prior treatment, indicating that the effect of VAR disappeared following termination 
of treatment (Fig. 3). 
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With regard to the stability of alcohol intake prior to and following deprivation, when alcohol  
intake prior to alcohol deprivation (mean of 5 days) was compared to alcohol intake during 
reaccess to alcohol on day 1, there was a significant effect of treatment, F (3, 42) = 5.0, 
p<0.01, and day F (1, 42) = 21.5, p<0.001, but no treatment X day interaction (Fig. 3A). 
Dunnett’s multiple comparisons against a single mean (VEH) revealed that, in the VEH-
treated group, there was no change in alcohol intake on day 1 of alcohol reaccess when 
compared to alcohol intake prior to alcohol deprivation (Fig. 3). VAR, in doses of 0.5 and 2.0 
mg/kg BW each reduced alcohol intake on day 1 of reaccess when compared to alcohol 
intake prior to the second deprivation (p<0.01, p<0.001, respectively), indicating a rapid 
onset of action of VAR (Fig. 3). 
With regard to water intake during the first 5 days of the alcohol reaccess period 
(Greenhouse-Geisser correction, ε=0.71), there was no effect of treatment, day, and no 
treatment X day interaction (Table 1). 
Effect of VAR on Alcohol and Water Intake Following the Third Alcohol Deprivation Cycle 
With regard to alcohol intake during the first 5 days of the alcohol reaccess period, there was 
a significant effect of treatment F (3, 42) = 8.9, p<0.001, and day F (4, 168) = 10.1, p<0.001, 
but no treatment X day interaction. Dunnett’s multiple comparisons against a single mean 
(VEH) revealed that VAR, in doses of 1.0, and 2.0 mg/kg BW, each reduced alcohol intake 
(p<0.001, and p<0.05, respectively) (Fig. 4). Dunnett’s multiple comparisons for each dose 
against a single mean (VEH) within day, revealed that the lowest dose of VAR (0.5 mg/kg 
BW) did not reduce alcohol intake on any of the 5 days of drug treatment. A higher dose of 
VAR (1.0 mg/kg BW) reduced alcohol intake on all 5 days of treatment (days 1, 2, and 4, 
p<0.05; days 3 and 5, p<0.01), and the highest dose of VAR (2.0 mg/kg BW), reduced 
alcohol intake on days 4 and 5 of treatment (p<0.01, and p<0.05, respectively). 
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With regard to alcohol intake after termination of drug treatment, there was no effect of 
treatment, a significant effect of day F (1, 41) = 6.5, p<0.05, and no treatment X day 
interaction. Dunnett’s multiple comparisons against a single mean (VEH) on post drug day 1 
revealed that alcohol intake was significantly higher than alcohol intake prior to deprivation 
(p<0.05). 
With regard to the stability of alcohol intake prior to and following deprivation, when alcohol 
intake prior to alcohol deprivation (mean of 5 days) was compared to alcohol intake during 
reaccess to alcohol on day 1, there was no effect of treatment, a significant effect of day F 
(1, 42) = 40.2, p<0.001, and a treatment X day interaction F (3, 42) = 3.1, p<0.05. Dunnett’s 
multiple comparisons against a single mean (VEH) revealed that, in the VEH-treated group, 
there was no change in alcohol intake on day 1 of alcohol reaccess when compared to 
alcohol intake prior to alcohol deprivation (Fig. 4). VAR, in doses of 0.5 and 1.0 mg/kg BW 
each reduced alcohol intake on day 1 of reaccess when compared to alcohol drinking prior 
to alcohol deprivation (p<0.05, and p<0.001, respectively) indicating a rapid onset of action 
of VAR (Fig. 4).    
With regard to water intake during the first 5 days of the alcohol reaccess period 
(Greenhouse-Geisser correction, ε= 0.66), there was no effect of treatment, a significant 
effect of day F (2.6, 111.2) = 9.1, p<0.001, and no treatment X day interaction (Table 1). 
 
DISCUSSION 
Alcohol relapse is a primary concern for individuals struggling with AUD (Edwards and 
Orford, 1977; Paredes et al., 2008). Currently, there are only three FDA-approved 
medications for the treatment of AUD: disulfiram, acamprosate and naltrexone (NTX) 
(Williams, 2005).  Disulfiram (Antibuse®) acts by inhibiting the enzyme acetaldehyde 
dehydrogenase which results in a buildup of acetaldehyde during alcohol drinking which is 
accompanied by symptoms such as nausea and headache that result in reduced medication 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
compliance (National Center for Biotechnology Information, Disulfiram).  Acamprosate 
(Campral®) has side effects including diarrhea, headache, and nausea which can also result 
in low medication compliance (Williams, 2005). Naltrexone (Trexan®, Rivia®, Vivitrol®) has 
fewer side effects than either disulfiram or acamprosate but it is not effective for all 
alcoholics (Krystal, et al., 2001). Identifying new medications for the treatment of AUD is 
needed and finding a medication that can prevent a return to heavy drinking during a lapse 
from alcohol abstinence is of particular importance since repeated relapses can prolong and 
strengthen withdrawal signs and symptoms which can put an individual at higher risk for 
subsequent relapse (Becker and Littleton 1996; Booth and Blow, 1993; Koob, 2011).    
In the current study varenicline (VAR) lowered alcohol intake during alcohol reaccess 
following each of 3 alcohol deprivation periods.  VAR in doses of 1.0 mg/kg and 2.0 
mg/kg reduced alcohol intake during all 3 alcohol reaccess periods and a dose of 0.5 
mg/kg reduced alcohol intake during the first 2 alcohol reaccess periods. The 
mechanism underlying VARs ability to reduce alcohol intake is not clear.  It is well known 
that alcohol increases the release of dopamine (DA) in the nucleus accumbens (NAc) during 
the first hour following peripheral or central alcohol administration (Di Chiara and Imperato, 
1988; Ericson et al., 2009) or following alcohol consumption (Weiss et al., 1993).  This 
increased DA release is thought to mediate the reinforcing (euphoric) effects of alcohol that 
contribute to alcohol drinking (Di Chiara and Imperato, 1988; Koob, 1992; Samson et al., 
1992; Weiss et al., 1993).  VAR also releases DA in the NAc during the first hour following 
central administration, though to a lesser degree than does alcohol, and continues to 
stimulate DA release for several hours following administration (Ericson et al., 2009).  
However, interestingly, co-administration of VAR and alcohol into the NAc at the same time 
inhibits alcohol-induced DA release (Ericson et al., 2009).  It is not known whether the ability 
of VAR to reduce alcohol intake is due to the fact that VAR blocks alcohol-induced DA 
release during the first hour of brain exposure to alcohol, thus reducing alcohol-induced 
euphoria and reducing the motivation to drink, or whether the VAR-induced stimulation of DA 
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release at later time intervals acts through a “drug substitution” mechanism to reduce alcohol 
withdrawal symptoms and craving, and hence the motivation for alcohol drinking. Both of 
these explanations may be correct depending on the stage of the addiction process being 
examined since early alcohol drinking, in nonaddicted individuals, is thought to be reinforced 
by alcohol-induced euphoria while alcohol drinking in alcohol-dependent individuals is 
thought to be reinforced by alcohol-induced attenuation of withdrawal symptoms and 
craving.   
This study illustrates the potential of VAR to reduce alcohol intake during reaccess to alcohol 
following alcohol deprivation but potential limitations should be considered when translating 
the findings. First, the subject population was rats selectively bred for high voluntary alcohol 
intake (alcohol-preferring or P rats).  Therefore, the findings may be more relevant for 
individuals who are genetically predisposed toward alcohol drinking, that is, people with a 
family history of alcoholism (family history positive or FHP), than for the general population 
(for review see Begleiter and Porjesz, 1990; Porjesz and Begleiter, 1991; Rice et al., 1995). 
Second, side effects are a potential limitation of any medication used to treat AUD.  While 
VAR does not have side effects that are as extensive as are those of antibuse, side effects 
do exist (headache, nausea, insomnia) (Drovandi et al., 2016) and are relatively comparable 
to those of other drugs approved for the treatment of AUD  such as naltrexone 
(Srisurapanont and Jarusuraisin, 2005) and acamprosate  (Carmen et al., 2004).  Early 
reports of VAR-induced altered behavior, which resulted in a 2015 FDA warning regarding 
the use of VAR, were not substantiated and the FDA revised the warning in 2016 and stated 
that VAR does not pose serious mental health risks.  Importantly, there appears to be 
minimal side effects of VAR reported in individuals with AUD (McKee et al., 2009; Mitchell et 
al., 2012, Verplaetse et al., 2016a, 2016b).  
The evidence supporting a role for VAR in the treatment of AUD continues to accumulate.  
We have previously reported that, in rats, VAR reduces alcohol intake when given over 
prolonged periods of time (Froehlich et al., 2016), when given alone or in combination with 
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naltrexone (Froehlich et al., 2016, 2017), when given prior to initial alcohol exposure 
(Froehlich et al., 2017) and, in the current study, when given during repeated cycles of 
alcohol reaccess following alcohol deprivation.  The versatility of VAR in reducing alcohol 
drinking, in a variety of situations, suggests that VAR may be a flexible pharmacotherapeutic 
agent for the treatment of AUDs.    
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Figure Legends 
Figure 1:  Alcohol intake in male P rats given scheduled access to (15% or 30% v/v) for 8 
hours a day, for 17 days followed by 4 hours a day for 11 days, and 2 hours a day for 28 
days prior to the initiation of drug treatment. Each point represents the mean ± SEM.  
Figure 2: (A) Effect of oral varenicline (VAR) (0.5 1.0 or 2.0mg/kg BW) or vehicle (VEH) on 
alcohol intake in male P rats given access to alcohol (15% or 30%) for 2 hours per day 
during the first alcohol reaccess cycle. (B) Effect of VAR or VEH on mean alcohol intake 
over the 5 days of drug treatment. **p<0.01, and ***p<0.001 versus vehicle. Each point 
represents mean ± SEM. 
 
Figure 3: (A) Effect of oral varenicline (VAR) (0.5 1.0 or 2.0mg/kg BW) or vehicle (VEH) on 
alcohol intake in male P rats given access to alcohol (15% or 30%) for 2 hours per day 
during the second alcohol reaccess cycle. (B) Effect of VAR or VEH on mean alcohol intake 
over the 5 days of drug treatment. **p<0.01, and ***p<0.001 versus vehicle. Each point 
represents mean ± SEM. 
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Figure 4: (A) Effect of oral varenicline (VAR) (0.5 1.0 or 2.0mg/kg BW) or vehicle (VEH) on 
alcohol intake in male P rats given access to alcohol (15% or 30%) for 2 hours per day 
during the third alcohol reaccess cycle. (B) Effect of VAR or VEH on mean alcohol intake 
over the 5 days of drug treatment. **p<0.01, and ***p<0.001 versus vehicle. Each point 
represents mean ± SEM. 
 
Table 1. 
  Treatment  
Mean 2-hr water intake 
during 5 days of VAR 
treatment  
Postdrug day 1  
Alcohol Reaccess 1 
 
VEH 
 
 
1.86 ± 0.57 
 
 
0.48  ± 0.33 
 
0.5 mg VAR 
 
1.39 ± 0.40 
 
0.74 ± 0.53 
 
1.0 mg VAR 
 
1.57 ± 0.33 
 
0.78 ± 0.55 
 
2.0 mg VAR 
 
1.44 ± 0.22 
 
1.50 ± 0.57 
 
Alcohol Reaccess 2 
 
VEH 
 
 
1.48 ± 0.45 
 
 
3.37  ± 2.89 
 
0.5 mg VAR 
 
0.64 ± 0.21 
 
1.32  ± 0.48 
 
1.0 mg VAR 
 
1.50 ± 0.35 
 
1.61  ± 1.05 
 
2.0 mg VAR 
 
1.63  ± 0.29 
 
1.69 ± 0.56 
 
Alcohol Reaccess 3 
 
VEH 
 
 
1.09  ± 0.18 
 
 
0.95  ± 0.4 
 
0.5 mg VAR 
 
1.87 ± 0.31 
 
0.77 ± 0.41 
 
1.0 mg VAR 1.58 ± 0.36 1.76 ± 0.68 
 
2.0 mg VAR 
 
 
1.39 ± 0.26 
 
 
2.42  ± 0.60 
 
 
Table Legend 
Table 1. Effect of Varenicline (VAR) (0.0, 0.5, 1.0, or 2.0 mg/kg BW) on mean 2-hour water 
intake (ml/kg BW ± SEM/2 h) in each of the 3 alcohol reaccess cycles.  
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